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Abstract Once migraine becomes chronic and has
transformed into a form of headache that occurs daily or
almost, the treatment options available are few and com-
plex. This makes it important to take action before this
point is reached, using all the measures that can be
obtained from our current knowledge of chronic migraine
(or transformed migraine) on the one hand, and on the
potential factors of chronification (or transformation) on
the other. Therefore, in order to reduce the risk of migraine
chronification, it would appear important to: (a) administer
suitable preventive treatments for subjects who have been
suffering from migraines C4 days a month for C3 months;
(b) take special care not to overuse symptomatic medica-
tions, particularly when they contain substances with a
sedative effect; and (c) investigate the concomitant pres-
ence of depression, hypertension and excess weight and
administer appropriate treatment when present.
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Introduction
In most cases, the natural history of migraine without aura
(MO) follows a favourable trend, with a reduction in the
frequency and severity of attacks until, in some cases, they
disappear completely, often many years after onset and
usually after the age of 50–55 years [1].
Conversely, over the years, a minority of subjects suf-
fering from MO experiences a gradual worsening, partic-
ularly as regards the frequency of the attacks, which
eventually leads to the regular presence of headaches more
than 15 days every month, if not every day or almost. In
these cases, we talk about chronic migraine (CM) or
transformed migraine (TM).
From the very first reports of this possible worsening
evolution of MO, the attention of researcher was, quite
rightly, focussed on identifying the factors for the trans-
formation of MO into CM or TM. In other words, it was
immediately clear how important it was in order to
understand why some subjects, unlike the majority, expe-
rience chronification rather than a remission of their MO,
to investigate the existence of potentially negative prog-
nostic elements, by performing comparative analyses on
large case series. This type of research constitutes the
essential bases for being able to organise adequate strate-
gies to treat or, better still, prevent CM or TM.
In order to be able to debate this issue in a complete
manner and succeed in identifying the ways in which MO
chronification can be avoided, we first need to consider, on
a one-by-one basis, the protagonists of the case—MO, CM
or TM—and the potential factors of transformation, eval-
uating what we know for sure and what we can suggest for
a better and clinically more tangible definition of them.
Migraine without aura
Since the International Headache Society (HIS) published
its classification in 1988 [2], at least as regards the
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characterisation of the individual attacks, MO has had a
universally accepted position and set of diagnostic criteria.
As further evidence of this, it did not undergo any variation
in the subsequent edition, issued in 2004 (ICHD-II) [3]. In
these classifications, MO is included as a migraine subtype
(code 1) with a second diagnostic level (code 1.1), with no
further subdivision.
A third diagnostic level for MO was recently proposed
[4, 5] based on the frequency of attacks, more specifically
according to the number of migraine days per month,
According to which the code 1.1.1 refers to MO that occurs
less than 4 days a month (infrequent MO), code 1.1.2
indicates MO that involves between 4 and 9 migraine days
per month (frequent MO), and code 1.1.3 MO that presents
10–20 days a month (CM or very frequent MO).
This subdivision has a corresponding treatment plan to
be followed: subjects with infrequent MO can be treated
with symptomatic therapy alone, those with frequent MO
must have preventive therapy, whilst continuing to take
their current symptomatic therapy, provided it is effica-
cious and well tolerated and patients with CM (or very
frequent MO) must follow preventive therapy and should
change their symptomatic treatment, even when it is effi-
cacious, to avoid running the risk of worsening their MO
due to overuse.
The utility of a classification that considers the fre-
quency with which MO presents, making a distinction
between the various levels of progressive ‘‘severity’’, is
further iterated by the fact that high attack frequency
constitutes a prognostic element that is predictive of MO
chronification [6, 7].
Chronic migraine and/or transformed migraine
Although with MO we are well aware of what we are
talking about, the same consensus does not exist for CM
and TM. The current edition of the International Classifi-
cation of Headache Disorders (ICHD-IIR del 2006) [8]
resolves the issue by adopting the term CM with corre-
sponding diagnostic criteria that are significantly different
from those formulated in the ICHD-II published in 2004.
Neither classification makes any reference to the term TM
introduced by Mathew et al. [9] in the 1980s and subse-
quently widely adopted thanks to its practical classification
and simple definition by Silberstein et al. [10].
In our recent proposal for a review of the migraine
classification, mentioned in the previous paragraph, in
which MO is split into three subtypes according to the
number of migraine days per month, TM is considered a
complication of migraine [4, 5, 11]. In this way, CM is a
very frequent MO that maintains all the clinical charac-
teristics typical of migraine, whereas TM is a form of MO
that is modified (i.e. complicated) with respect to the past
not merely because the number of headache days per
month is higher than that of CM, but also because the
headache does not present the aspects typical of migraine.
This makes TM a more severe form and one that is more
difficult to treat than CM, the latter being more likely to
revert to frequent or infrequent MO than TM [7, 12].
The terms ‘‘chronic’’ and ‘‘chronification’’ are ambigu-
ous and misleading. We believe that they should be disre-
garded and the terms ‘‘very frequent MO’’ (code 1.1.3) and
‘‘TM’’ (code 1.5.1) used instead, with the corresponding
diagnostic criteria listed in Table 1. If we really want to
keep the term CM, which it would appear that certain
Table 1 Proposed revision of migraine classification, and proposed
diagnostic criteria for the three migraine without aura subtypes, and
for transformed migraine
1.1 Migraine without aura
1.1.1 Infrequent migraine without aura
1.1.2 Frequent migraine without aura
1.1.3 Very frequent migraine without aura
1.1.3.1 With medication overuse
1.1.3.2 Without medication overuse
1.5 Complications of migraine
1.5.1 Transformed migraine
1.5.1.1 With medication overuse
1.5.1.2 Without medication overuse
1.1.1 Infrequent migraine without aura
Diagnostic criteria
A. headache fulfilling criteria C and D for 1.1 migraine without
aura on B3 days/month for C3 months
B. Not attributed to another disorder
1.1.2 Frequent migraine without aura
Diagnostic criteria
A. headache fulfilling criteria C and D for 1.1 migraine without
aura on [3 but \10 days/month for C3 months
B. Not attributed to another disorder
1.1.3 Very frequent migraine without aura
Diagnostic criteria
A. Headache fulfilling criteria C and D for 1.1 migraine
without aura on C10 but B20 days/month for C3 months
B. Not attributed to another disorder
1.5.1 Transformed migraine
Diagnostic criteria
A. Headache (tension-type and/or migraine) on [20 days/
month for C1 year and never with more than 5 consecutive
headache-free days
B. Occurring in a patient who has had at least five attacks
fulfilling criteria for 1.1 migraine without aura
C. On C10 days/month for C1 year, headache has fulfilled
criteria for pain and associated symptoms of migraine without
aura or patient has been successfully treated with an ergot or
triptan
D. Not attributed to another disorder
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authors are reluctant to give up, it could be used to define
very frequent MO, but not TM, which can no longer be
considered a simple migraine, rather a fully blown compli-
cated migraine. In any case, what does not seem clinically
acceptable is to contemplate including under the current
single denomination of CM as defined by the ICHD-IIR [8],
patients with such a difference in gravity as to warrant a
subdivision into two well-defined groups: very frequent MO
(or CM, if we wish) on the one hand, and TM on the other.
Potential factors of chronification/transformation
Regardless of whether we want to call it chronification or
transformation, the important thing is to try and identify
those factors, situations and any concomitant conditions
that could favour a progression from MO towards CM or
even TM.
Mathew et al. [9] identified overuse of symptomatic
medications, depression, hypertension and surgical meno-
pause as elements that are often present when MO trans-
forms into TM.
Since then, several studies have dealt with the subject
and further elements have been added [13–16], although
some of them may appear dubious and need to be con-
firmed or refuted by further specific research, and to date
the factors originally suggested by Mathew et al. [9]
remain those most widely accepted.
Of the factors identified more recently, the potential role
of obesity [17, 18] and cerebral venous sinus alterations
[19] are undoubtedly of particular interest.
A comparative analysis [7] that we recently conducted
between (a) a group of patients who at first observation
presented with MO that either remained such, improved or
completely disappeared over time and (b) a group of
patients, similar to the first, originally affected by MO but
that, over the years, evolved towards CM or TM, shows
that a high frequency of attacks in both men and women
and depression in men at first observation, i.e. when the
diagnosis was still one of ‘‘simple’’ MO, constitute factors
predictive of chronification/transformation. In addition,
there is statistically significant evidence that depression in
women and hypertension in both sexes, even when not
present at first observation, tends to present in MO patients
evolving towards CM/TM more frequently than in MO
patients who either remain stable or improve over time.
Strategies for combatting the chronification/
transformation of MO
Despite all the limits due to (a) a clinical classification of
CM/TM that is not yet unanimously accepted and (b) an
as yet incomplete and uncertain identification of the
potential negative prognostic factors in the natural his-
tory of MO, at the current state of knowledge, it would
appear possible and useful to adopt measures aimed at
preventing the chronification of MO. The great impor-
tance of this operation derives also from the consider-
able difficulties of treating CM/TM once it is established
[20, 21].
The first action to be taken is to treat MO while there is
still time—‘‘before the horse has bolted’’ [22], so to speak.
For this to be plausible, we should take into consideration
the data produced by an epidemiological study conducted
in the USA [23], according to which unfortunately, just
6–7 % of subjects with MO in the general population
consults a doctor and receives a correct diagnosis, suitable
treatment and regular follow-up. This highlights the
importance of transmitting adequate and correct informa-
tion on migraine to both general practitioners and patients
[24]. Treating MO whilst there is still time means making
use, in those subjects who regularly suffer more than 3
migraine days a month, not merely of the necessary
symptomatic medications, but above all, all the possible
preventive treatments available, which, fortunately, are
now fairly numerous.
Correct use of prophylactic treatments can also con-
tribute to a better approach to the second important step in
preventing MO chronification: avoiding overuse of symp-
tomatic medications which, as has been extensively pro-
ven, can create a vicious circle of dependency and
addiction, with a progressive worsening in the migraine
situation [25]. Since the highest risk symptomatic medi-
cations in this sense are products containing a combination
that also includes substances with a sedative action [26], it
would appear appropriate for very frequent MO patients,
until such time as they benefit from the preventive treat-
ments prescribed, to avoid or at least limit the use of this
type of symptomatic medication and also seek psycholog-
ical support.
The third, fundamental measure for reducing the risk of
chronification consists in dedicating the greatest possible
care to the existence of potential comorbidities. Although it
has been known for some time that certain conditions
present more frequently in MO subjects [27, 28] and others
have been identified more recently, not all the potential
comorbidities of MO favour chronification. As far as we
know at the current time, the highest-risk conditions are
depression [9, 29], hypertension [9] and excess weight [17,
18]. As far as possible, these should be prevented in MO
subjects and where they are already present, they require
particularly careful treatment. In this sense, the fact that the
medications that provide efficacious prophylaxis for MO
also include antihypertensives and antidepressants may
constitute an advantage.
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